Google
STTK — SHATTUCK LABS INC (Healthcare >> Biotechnology)
STTK FAQ
What is STTK's ROE?
SHATTUCK LABS INC reports a Return on Equity (ROE) of -52.04%.
What is STTK's dividend yield?
SHATTUCK LABS INC offers a dividend yield of 0.00%.
What is STTK's Deepscope Quality Score?
Deepscope rates STTK's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy STTK?
Deepscope's AI Timing Score for STTK is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does STTK belong to?
SHATTUCK LABS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.80
Price
0.05
(1.05%)
Day Change
|
|
|---|
STTK, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.80 |
| PBV / Sector |
3.91 / 4.58
|
| Earning Per Share | -0.64 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
3.68 M
GREAT
|
| Average 1W Daily Value |
3.59 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:40 |
| Symbol | STTK |
| Name | SHATTUCK LABS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 76.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 374.97 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 500 West 5th Street, Austin, TX, United States, 78701
Phone: 512 900 4690
Website: https://www.shattucklabs.com
Sector: Healthcare >> Biotechnology
Description: Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
